Prolonged Hypocalcemia After Treatment With Zoledronic Acid in a Patient With Prostate Cancer and Vitamin D Deficiency
Authors:
- 15 April 2004
- journal article
- other
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (8) , 1531-1532
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Severe Hypocalcemia after Intravenous Bisphosphonate Therapy in Occult Vitamin D DeficiencyNew England Journal of Medicine, 2003
- Hypocalcemia Following Pamidronate Administration for Bone Metastases of Solid TumorJournal of Pain and Symptom Management, 2003
- Zoledronic AcidDrugs, 2003
- Bendamustine in the treatment of chronic lymphocytic leukemia: Results and future perspectivesSeminars in Oncology, 2002
- Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral DensityNew England Journal of Medicine, 2002
- The New Bisphosphonate, Zometa®(Zoledronic Acid), Decreases Skeletal Complications in Both Osteolytic and Osteoblastic Lesions: A Comparison to PamidronateCancer Investigation, 2002
- Vitamin D Insufficiency and Hyperparathyroidism in a Low Income, Multiracial, Elderly PopulationThe Journal of Clinical Endocrinology & Metabolism, 2000
- A Dose-Finding Study of Zoledronate in Hypercalcemic Cancer PatientsJournal of Bone and Mineral Research, 1999
- Hypocalcemia Associated with AlendronateAnnals of Internal Medicine, 1999
- Hypovitaminosis D in Medical InpatientsNew England Journal of Medicine, 1998